La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology

3 pages
Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology PR Newswire VIENNA, Austria, October 1, 2012 VIENNA, Austria, October 1, 2012 /PRNewswire/ -- INTENDED FOR EUROPEAN MEDIA ONLY Results from a Phase I/II trial of the investigational compound lenvatinib (E7080), a multi-targeted, kinase inhibitor, in people with advanced hepatocellular cancer have been presented at the ESMO 2012 Congress (European Society for Medical Oncology) taking place on Friday 28 September - [1]Tuesday 2 October. Two other studies were presented, reporting the results of lenvatinib in the treatment of recurrent glioblastoma (the most common type of brain cancer which is almost universally fatal) and lenvatinib in [2],[3]combination with everolimus in metastatic renal cell carcinoma. The following Eisai posters were presented at this year's ESMO 2012 Congress: A Phase 2 Trial of the Multi-targeted Kinase Inhibitor Lenvatinib (E7080) in Lenvatinib (E7080) Patients With Recurrent Glioblastoma (GBM) and Disease Progression Following Abstract No: 417PD Prior Bevacizumab Treatment Poster Session D.A. Reardon, E. Pan, J. Fan, J. Mink, D. Barboriak, J.J. Vredenburgh, A. Saturday 29th Desjardins, K. Peters, J.P. O'Brien, P.
Voir plus Voir moins
Eisai Presents new Research for
Investigational Compound Lenvatinib at the
European Society for Medical Oncology
PR Newswire
VIENNA, Austria, October 1, 2012
VIENNA, Austria
,
October 1, 2012
/PRNewswire/ --
INTENDED FOR EUROPEAN MEDIA ONLY
Results from a Phase I/II trial of the investigational compound lenvatinib
(E7080), a multi-targeted, kinase inhibitor, in people with advanced
hepatocellular cancer have been presented at the ESMO 2012 Congress
(European Society for Medical Oncology) taking place on Friday 28 September -
Tuesday 2 October.
[1]
Two other studies were presented, reporting the results
of lenvatinib in the treatment of recurrent glioblastoma (the most common
type of brain cancer which is almost universally fatal) and lenvatinib in
combination with everolimus in metastatic renal cell carcinoma.
[2],[3]
The following Eisai posters were presented at this year's ESMO 2012 Congress:
A Phase 2 Trial of the Multi-targeted
Kinase Inhibitor Lenvatinib (E7080) in
Lenvatinib (E7080)
Patients With Recurrent Glioblastoma
(GBM) and Disease Progression Following
Abstract No: 417PD
Prior Bevacizumab Treatment
Poster Session
D.A. Reardon, E. Pan, J. Fan, J. Mink,
D. Barboriak, J.J. Vredenburgh, A.
Saturday 29th
Desjardins, K. Peters, J.P. O'Brien, P.
September 13:00-14:00
Wen
A Phase Ib Clinical Trial of the
Lenvatinib (E7080)
Multi-targeted Kinase Inhibitor
Lenvatinib (E7080) in Combination With
Abstract No: 814P
Everolimus for Treatment of Metastatic
Renal Cell Carcinoma (RCC)
Poster Session
A.M. Molina, T.E. Hutson, J.M.G.
Saturday 29th
Larkin, A. Gold, C. Andresen, K. Wood,
September 13:00-14:00
R. Motzer, M.D. Michaelson
Lenvatinib (E7080)
Phase I/II Trial of Lenvatinib (E7080),
a Multi-targeted Tyrosine Kinase
Abstract No: 737P
Inhibitor, in Patients with Advanced
Hepatocellular Carcinoma (HCC)
Poster Session
K. Ikeda, H. Kumada, M. Kudo, S.
Sunday 30th September
Kawazoe, Y. Osaki, M. Ikeda, T.Okusaka,
13:00-14:00
T. Suzuki, J P O'Brien, K. Okita
"Presentation of these data at ESMO demonstrates continued progress in the
development of lenvatinib. Eisai's
human health care
mission is to help address
unmet medical needs and provide healthcare benefits to patients and their
families," says Dr Jim O'Brien, Eisai's Lenvatinib International Team Lead. "Our
commitment to the development of lenvatinib underscores our commitment to
this important mission."
Notes to Editors
Lenvatinib (E7080)
Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases
(RTKs), including KDR (VEGFR-2), Flt-1 (VEGFR-1), FGFR1, PDGFR-β and c-kit
involved in angiogenesis and tumour proliferation.
[4],[5]
It is currently being
investigated as a treatment for thyroid, hepatocellular, endometrial and other
solid tumour types.
Eisai in Oncology
Eisai is dedicated to discovering, developing and producing innovative oncology
therapies that can make a difference and impact the lives of patients and their
families. This passion for people is part of Eisai's human health care (hhc)
mission, which strives for better understanding of the needs of patients and
their families to increase the benefits health care provides. Our commitment to
meaningful progress in oncology research, built on scientific expertise, is
supported by a global capability to conduct discovery and preclinical research,
and develop small molecules, therapeutic vaccines, and biologic and supportive
care agents for cancer across multiple indications.
About Eisai:
Eisai recently expanded their UK Hatfield commercial, research and
manufacturing facility which now supports the company's growing EMEA
business.
Eisai concentrates its R&D activities in three key areas:
Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
Oncology including: anticancer therapies; tumour regression, tumour suppression,
antibodies, etc
Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis,
psoriasis, inflammatory bowel disease
With operations in the U.S.,
Asia
,
Europe
and its domestic home market of
Japan
, Eisai employs more than 11,000 people worldwide. In
Europe
, Eisai
undertakes sales and marketing operations in over 20 markets, including the
United Kingdom
,
France
,
Germany
,
Italy
,
Spain
,
Switzerland
,
Sweden
,
Ireland
,
Austria
,
Denmark
,
Finland
,
Norway
,
Portugal
,
Iceland
,
Czech Republic
,
Slovakia
,
the Netherlands
,
Belgium
,
Luxembourg
, the
Middle East
and
Russia
.
For further information please visit our web site http://www.eisai.com.
References:
1. Ikeda, K. Kumada, H. Kudo, et al. Phase I/II trial of Lenvatinib (E7080), a
multi-targeted tyrosine kinase inhibitor, in patients with advanced
hepatocellular carcinoma. Poster presented at the ESMO Congress,
Vienna
,
2012
2. Reardon, D.A. Pan, E. Fan, et al. A Phase 2 Trial of the multi-targeted kinase
inhibitor lenvatinib (E7080) in patients with recurrent glioblastoma and disease
progression following prior bevacizumab treatment. Poster presented at the
ESMO Congress,
Vienna
, 2012
3. Molina, AM. Hutson, TE. Larkin, et al. A Phase Ib clinical trial of the multi-
targeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for
the treatment of metastatic renal cell carcinoma. Poster presented at the
ESMO Congress,
Vienna
, 2012
4. Matsui J, Funahashi Y, Uenaka T et al. Multi-kinase inhibitor E7080 suppresses
lymph node and lung metastases of human mammary breast tumour MDA-MB-
231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and
VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.
5. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that
targets multiple kinases, has potent anti-tumour activities against stem cell
factor producing human small cell lung cancer H146, based on angiogenesis
inhibition. Int J Cancer 2008; 122: 664-71.
Date of preparation:
September 2012
Job code: Lenvatinib-UK0006
Un pour Un
Permettre à tous d'accéder à la lecture
Pour chaque accès à la bibliothèque, YouScribe donne un accès à une personne dans le besoin